

PHARMACEUTICAL 2023











RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of Immuneering Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immuneering Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Immuneering Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 162% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	108,747
Cost of Goods Sold	158
Intangible Assets	7,099
Liabilities, Current	8,054
Liabilities, Non-Current	4,463
Other Assets	5,151
Other Compr. Net Income	19
Other Expenses	30
Other Liabilities	0
Other Net Income	1,231
Other Revenues	317
Property and Equipment	1,370
Research and Development	36,267
Selling, General and Administrative Expense	15,607

Output Variable	Value in 1000 USD
Assets	122,367
Liabilities	12,517
Expenses	52,062
Revenues	317
Stockholders Equity	109,850
Net Income	-50,514
Comprehensive Net Income	-50,504
Economic Capital Ratio	205%

